The Dark Side of Globalization: Lack of Universal Levodopa Availability.
作者信息
Merello Marcelo
机构信息
Movement Disorders Section. Neuroscience Department Fleni Universidad Catolica Argentina (UCA). Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET).
出版信息
Mov Disord Clin Pract. 2018 Nov 16;6(1):7-8. doi: 10.1002/mdc3.12704. eCollection 2019 Jan.
Abstract
摘要
相似文献
1
The Dark Side of Globalization: Lack of Universal Levodopa Availability.全球化的阴暗面：左旋多巴供应缺乏普遍性。
Mov Disord Clin Pract. 2018 Nov 16;6(1):7-8. doi: 10.1002/mdc3.12704. eCollection 2019 Jan.
2
Chronic exposure to dopamine agonists affects the integrity of striatal D receptors in Parkinson's patients.慢性暴露于多巴胺激动剂会影响帕金森病患者纹状体 D 受体的完整性。
Neuroimage Clin. 2017 Aug 24;16:455-460. doi: 10.1016/j.nicl.2017.08.013. eCollection 2017.
3
Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.培高利特：在帕金森病中的药理学和治疗用途的综述。
CNS Drugs. 1997 Apr;7(4):328-40. doi: 10.2165/00023210-199707040-00005.
4
Dopamine agonist therapy in early Parkinson's disease.早期帕金森病的多巴胺激动剂治疗
Cochrane Database Syst Rev. 2008 Apr 16(2):CD006564. doi: 10.1002/14651858.CD006564.pub2.
5
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.长效多巴胺受体激动剂和单胺氧化酶 B 抑制剂与左旋多巴作为帕金森病（PD MED）初始治疗的长期疗效比较：一项大型、开放标签、实用随机试验。
Lancet. 2014 Sep 27;384(9949):1196-205. doi: 10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11.
6
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.帕金森病治疗中的药代动力学优化：最新进展
Clin Pharmacokinet. 2006;45(2):109-36. doi: 10.2165/00003088-200645020-00001.
7
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.普拉克索与罗匹尼罗治疗帕金森病的比较。
Ideggyogy Sz. 2022 Jan 30;75(1-02):39-49. doi: 10.18071/isz.75.0039.
8
Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.帕金森病患者肠道输注左旋多巴后纹状体多巴胺水平持续稳定。
Mov Disord. 2017 Feb;32(2):235-240. doi: 10.1002/mds.26848. Epub 2016 Nov 17.
9
Clinical pharmacology of dopamine agonists in Parkinson's disease.帕金森病中多巴胺激动剂的临床药理学
Drugs Aging. 1998 Nov;13(5):381-9. doi: 10.2165/00002512-199813050-00004.
10
Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan.日本多巴胺激动剂治疗帕金森病的成本效益分析。
Pharmacoeconomics. 2001;19(8):875-86. doi: 10.2165/00019053-200119080-00009.
本文引用的文献
1
A Nationwide Survey of Parkinson's Disease Medicines Availability and Affordability in Nigeria.尼日利亚帕金森病药物可及性与可负担性的全国性调查。
Mov Disord Clin Pract. 2018 Nov 16;6(1):27-33. doi: 10.1002/mdc3.12682. eCollection 2019 Jan.
2
Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.在帕金森病晚期患者中每日摄入羽扇豆：一项 16 周、非劣效性、随机、交叉、先导研究。
Parkinsonism Relat Disord. 2018 Apr;49:60-66. doi: 10.1016/j.parkreldis.2018.01.014. Epub 2018 Jan 11.
3
Levodopa: A new look at an old friend.左旋多巴：老朋友的新面貌。
Mov Disord. 2018 Jul;33(6):859-866. doi: 10.1002/mds.27216. Epub 2017 Nov 27.
4
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.帕金森病左旋多巴治疗前的现代时期：来自撒哈拉以南非洲地区对运动并发症的见解。
Brain. 2014 Oct;137(Pt 10):2731-42. doi: 10.1093/brain/awu195. Epub 2014 Jul 17.
5
Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian cohorts.西班牙和喀麦隆队列中帕金森病临床特征的比较。
J Neurol Sci. 2014 Jan 15;336(1-2):122-6. doi: 10.1016/j.jns.2013.10.021. Epub 2013 Oct 22.
6
The challenge of Parkinson's disease management in Africa.非洲帕金森病管理面临的挑战。
Age Ageing. 2007 Mar;36(2):122-7. doi: 10.1093/ageing/afl172. Epub 2007 Jan 29.
7
L-dopa in the treatment of Parkinsonism in Africans.
East Afr Med J. 1972 Feb;49(2):112-5.
8
Parkinson's disease in the African.非洲的帕金森病
Cent Afr J Med. 1978 Jan;24(1):5-8.
Zotero 插件